Taurine and Morning or Evening Interval Exercise in Women With Obesity
Tests taurine with morning or evening exercise in adult women with obesity.
Plain-language title generated from the registry record
Registry title: Effects of Taurine Supplementation and Morning or Evening High-intensity Exercise on Circadian Clock Genes and Inflammatory Parameters in Adult Women With Obesity
Key facts
- Where
- Ribeirão Preto, BrazilSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 45 with obesity and mild ongoing inflammation. It tests taurine and morning or evening high-intensity exercise.
- Age
- 18 to 45 years
- Sex
- Women only
- Disease stage
- Body mass index (BMI) of 30-39.9 kg/m² for at least 3 years, body fat of 35% or more, and hs-CRP above 1 and below 10 mg/L without signs of infection.
- Earlier treatment
- No structured exercise programs, restrictive diets or other nutritional interventions in the 3 months before the study. Stable body weight in those 3 months.
- Biomarker or test result
- Blood hs-CRP level above 1 and below 10 mg/L.
Main reasons for not taking part
- hs-CRP of 10 mg/L or higher
- Signs of infection or an acute inflammatory process, or a diagnosed chronic inflammatory disease
- Insulin-dependent diabetes, established cardiovascular disease, uncontrolled hypertension, or significant sleep disorders
- Regular use of immunosuppressants, glucose-lowering drugs, corticosteroids or anti-inflammatory drugs
- Current smokers or chronic alcohol users
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT07910747, who can take part
Where in Brazil
- School of Physical Education and Sport of Ribeirao Preto, University of Sao Paulo (EEFERP USP)Ribeirão Preto, BrazilNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Sao Paulo
- Trial code
- NCT07910747
- Record updated
- 2 November 2026
- Original description
The goal of this clinical trial is to evaluate whether taurine supplementation, alone or combined with high-intensity interval training (HIIT) performed in morning or evening, affects circadian clock gene expression and inflamatory markers in adult women with obesity. The main questions it aims to answer are:Read full original descriptionShow less
Effects of Taurine Supplementation Combined With Morning or Evening High-intensity Exercise on Circadian Clock Genes and Inflammatory Parameters in Adult Women With Obesity
The goal of this clinical trial is to evaluate whether taurine supplementation, alone or combined with high-intensity interval training (HIIT) performed in morning or evening, affects circadian clock gene expression and inflamatory markers in adult women with obesity. The main questions it aims to answer are:
* Is the modulation of circadian clock gene expression associated with the anti-inflammatory effects of taurine? * Does the timing of HIIT (morning or evening) affect circadian clock gene expression and inflammatory and metabolic responses? Researchers will compare six groups to evaluate the effects of taurine supplementation, HIIT performed in the morning or evening, and their combination.
Participants will:
* Take taurine (3g/day) or a matching placebo for 12 weeks, according to their assigned group; * Perform HIIT in the morning or evening if assigned to an exercise group; * Attend study visits at baseline (week 0) and after 12 weeks for assessments of metabolic and inflammatory parameters, circadian clock gene expression in peripheral blood mononuclear cells (PBMCs), as well as anthropometric measures, body composition and cardiorrespiratory fitness.
Inclusion: Participants must meet all of the following criteria:; Have a body mass index (BMI) of 30-39.9 kg/m² (class I or II obesity) for at least 3 years and a body fat percentage ≥35%; Have maintained stable body weight during the 3 months preceding the study; Have a predominantly nocturnal sleep schedule and no history of night-shift or rotating-shift work during the previous 6 months; Have not participated in structured exercise training programs or undertaken restrictive diets or other nutritional interventions during the 3 months preceding the study; Have serum high-sensitivity C-reactive protein (hs-CRP) levels >1 and <10 mg/L, consistent with low-grade systemic inflammation, in the absence of clinical or laboratory evidence of infection or an acute inflammatory process.
Exclusion: Present signs or symptoms suggestive of infection or an acute inflammatory process, including fever, flu-like symptoms, recent infections, use of antibiotics or anti-inflammatory medications, or recent vaccination; Have a diagnosed chronic inflammatory disease or have experienced an acute infectious process within the 2 weeks preceding the assessments; Have insulin-dependent diabetes mellitus, established cardiovascular disease, uncontrolled hypertension, or clinically significant sleep disorders; Regularly use medications such as immunosuppressants, glucose-lowering agents, corticosteroids, or anti-inflammatory drugs; Participants meeting any of the following criteria will be excluded:; Have hs-CRP levels ≥10 mg/L; Are current smokers or chronic alcohol users; Attendance at fewer than 80% of the scheduled training for participants allocated to HIIT groups.